paywalled: The risk of metachronous cancers in patients with small-intestinal carcinoid tumors: a US population-based study

 Blogger's Note: while rare, and there is no specific reference in this abstract, carcinoid ovarian cancer tumors do exist so this research will be of interest for those diagnosed, this blog has some research on ovarian carcinoid tumors

The risk of metachronous cancers in patients with small-intestinal carcinoid tumors: a US population-based study

"In conclusion, almost one-third of patients with SICs have an associated metachronous primary tumor. When these primaries occur prior to (but not after) the SIC diagnosis, the prognosis is worse than with an initial SIC. The type of malignancies associated with SICs may guide future screening efforts.."

open access: Quality of Clinical Trials in Gastro‐Entero‐Pancreatic Neuroendocrine Tumours

 Blogger's Note:
rare ovarian cancer endocrine/carcinoid tumors exist, therefore, a possible interest in this paper,  there may have been ovarian cancer tumors included in a study/ies,  but without looking at each individual study,  this paper does not isolate references to ovarian/ovary

         ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

Table 2 describes the study populations which may or may not have included OC endocrine/carcinoid tumors

Description of the study population in the 46 identified trials.

Characteristic

No. of Studies %

Tumour location

Pancreatic neuroendocrine tumour only

Carcinoid tumours only

Both tumours

With other endocrine cancer

Table 6. Search strategy to identify published phase II and III NET treatment trials.  (Blogger's Note: search included:  carcinoid, neuroendocrine, melanoma, thyroid but no references to 'ovarian' or 'ovary' nor any specifics in the supporting references)


Quality of Clinical Trials in Gastro‐Entero‐PancreaticNeuroendocrine Tumours

"In conclusion, we found that the quality of study design and reporting in NETs treatment trials published in the last decade is poor, especially for trials testing radionuclide treatment. While poor study design and reporting has been previously described for trials in other malignancies, some unique quality issues exist for NET trials such as the inclusion of heterogenous patient populations within individual studies coupled with poor reporting of study population parameters. This has a significant impact on trial interpretability both for clinical decision‐making and future trials.
In response, we include a list of recommendations to be considered in the design of future trials in this group of tumours to ensure that future trials provide a more informative picture of the risks and benefits of systemic therapy in this patient population. We hope that our study can serve as a baseline against which improvements in clinical trial design and reporting in this patient population can be compared."

abstract: Importance of Histologic Subtype in the Staging of Appendiceal Tumors.

Blogger's Note: common feature is mucinous cell type; understudied is familial appendiceal carcinoid

BACKGROUND:

Malignant neoplasms of the appendix have different behavior based on their histologic subtypes in anecdotal series. Current staging systems do not capture the diversity of histologic subtypes in predicting outcomes.

METHODS:

We queried all patients with appendiceal malignancies captured in the Surveillance, Epidemiology, and End Results (SEER) database from 1973 to 2007. Tumors were classified as colonic type adenocarcinoma, mucinous adenocarcinoma, signet ring cell type, goblet cell carcinoid, and malignant carcinoid. We compared incidence, overall survival, and disease-specific survival for these tumors on the basis of patient, tumor, and therapy characteristics. Estimates from Cox proportional hazard modeling were used to predict hazard ratios for differing histologic subtypes with similar tumor, node, metastasis system (TNM) stages.

RESULTS:

Of the 5672 patients identified, we included 5655 (99%) in our analysis. The 5-year disease-specific survival rates were 93% for malignant carcinoid, 81% for goblet cell carcinoid, 55% for colonic type adenocarcinoma, 58% for mucinous adenocarcinoma, and 27% for signet ring cell type. Predicted estimates of adjusted hazard ratios revealed an 8-fold difference between histologic subtypes for similar TNM stages.

CONCLUSIONS:

Histologic subtype is an important predictor of disease-specific survival and overall survival in patients with appendiceal neoplasms. Addition of the histologic subtype to the TNM staging is simple and may improve prognostication.

Echocardiographic imaging of tricuspid and pulmonary valve abnormalities in primary ovarian carcinoid tumor-abstract

Abstract

Carcinoid is a rare malignancy originating from enterochromaffin cells and is clinically characterized by flushing, diarrhea and bronchospasm, due to secretion of vasoactive substances. A dreaded complication is carcinoid heart disease, which mainly affects right cardiac chambers, resulting in thickened, immobile and retracted tricuspid and pulmonary valves. In the current report, a case of a 60-year old female presenting with symptoms of right heart failure is described. Transthoracic two-dimensional and real-time three-dimensional echocardiography findings, as well as biochemical markers, including pro-BNP and NT-pro-BNP, were consistent with carcinoid syndrome. The histological diagnosis of carcinoid was confirmed after surgical resection of an ovarian mass.

New Therapies for Neuroendocrine Tumors (carcinoid tumors)

Note: Medscape requires (free) registration to view

Overview of Neuroendocrine Tumors: Focus on Carcinoid Tumors and Syndrome

Overview of Neuroendocrine Tumors: Focus on Carcinoid Tumors and Syndrome
Neuroendocrine tumors (NETs)

NETs: A common and heterogenous group of solid malignant tumors »

Carcinoid tumors: A frequently occurring GI malignancy »

NETs: Survival rates are correlated with extent of disease and tumor differentiation »

The rising incidence of carcinoid tumors »

*note comments: Study to Evaluate Families with History of Carcinoid Cancer

Note:  this study is an NIH study and excludes those with a known genetic syndrome

Study to Evaluate Families with History of Carcinoid Cancer
By The Carcinoid Cancer Foundation (CCF)

The Natural History of Familial Carcinoid Tumor is recruiting participants who are interested in being part of a study that will “evaluate families with a history of carcinoid cancer to determine ways to improve early detection and to find the gene that may cause the tumors.”

If you are a member of a family in which two or more immediate blood relatives have had gastrointestinal carcinoid tumors, you may be eligible for this study. Unaffected spouses of family members diagnosed with carcinoid cancer are also requested to participate.